Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children.
Adenosine has become the drug of choice for termination of regular, normal QRS tachycardia. Initial studies in adult and pediatric patients have shown that the drug is effective for tachycardias using the atrioventricular (AV) node as an integral part of the tachycardia circuit and has few serious side effects. Experience with adenosine administration in children was reviewed to examine the diagnostic and therapeutic usefulness, effective dose, and adverse effects of adenosine. Adenosine was administered to 38 children during 50 separate electrophysiologic evaluations. Eleven patients had structural or acquired heart disease. Tachycardia mechanisms included orthodromic-reciprocating tachycardia using an accessory AV connection (23 patients), primary atrial tachycardia (6 patients), AV node reentrant tachycardia (3 patients), ventricular tachycardia (2 patients), postoperative junctional tachycardia (1 patient), and antidromic-reciprocating tachycardia (1 patient). Adenosine successfully terminated 51 of 53 episodes (96%) of tachycardia using the AV node, 5 of 10 primary atrial tachycardias, 1 of 1 junctional tachycardia, and 1 of 3 ventricular tachycardias. Reinitiation of tachycardia was seen after 16 of 58 successful terminations (28%), reducing the effectiveness to 39 of 53 (74%) for tachycardia requiring the AV node. Average effective dose was 132 micrograms/kg, range 50 to 250 micrograms/kg, and was slightly higher for peripheral (147 micrograms/kg) than for central (120 micrograms/kg) administration. Significant complications occurred in 4 of 38 patients, including atrial fibrillation, accelerated ventricular tachycardia, apnea, and 1 minute of asystole. Although adenosine is useful therapeutically and diagnostically in children with tachycardia, its effectiveness is limited by tachycardia reinitiation and adverse effects. Higher doses may be required for peripheral intravenous administration.
Department of Pediatrics, University of Minnesota Hospital and Clinics, Minneapolis.
J E
JE
Crosson
S P
SP
Etheridge
S
S
Milstein
P S
PS
Hesslein
A
A
Dunnigan
D000241:Adenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001049:Apnea / Q000139:chemically induced; D001146:Arrhythmia, Sinus / Q000139:chemically induced; D001281:Atrial Fibrillation / Q000139:chemically induced; D016275:Atrial Function / Q000187:drug effects; D001283:Atrioventricular Node / Q000187:drug effects; D001919:Bradycardia / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D004562:Electrocardiography / Q000187:drug effects; D004594:Electrophysiology; D006327:Heart Block / Q000175:diagnosis; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007275:Injections, Intravenous; D013610:Tachycardia / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000175:diagnosis / Q000188:drug therapy; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000188:drug therapy; D013806:Theophylline / Q000627:therapeutic use
D013806:Theophylline; D000241:Adenosine